Loading clinical trials...
Loading clinical trials...
The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation mark...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Sanofi
NCT01004575 · Coronary Artery Disease, Angioplasty, Transluminal, Percutaneous Coronary
NCT01241903 · Acute Coronary Syndrome, Angioplasty, Transluminal, Percutaneous Coronary, and more
NCT00269893 · Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary
NCT00269906 · Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary
NCT00345631 · Angioplasty, Transluminal, Percutaneous Coronary, Coronary Arteriosclerosis, and more
Los Angeles Cardiology Associates
Los Angeles, California
Anil V. Shah, MD
Santa Ana, California
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions